Indapamide
Indapamide: 1 brand, 9 generics; first approved Jul 06, 1983; generic available.
Generic available: 9 ANDA applications approved.
Brand (NDA) products
- LOZOLRLDSANOFI AVENTIS USNDA 01853819932 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2.5MG TABLET ORAL Discontinued — 1.25MG TABLET ORAL Discontinued —
Generic (ANDA) products (9)
- INDAPAMIDEANI PHARMSANDA 07520119982 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Discontinued — 2.5MG TABLET ORAL Discontinued — - INDAPAMIDEAUROBINDO PHARMA USAANDA 07510519982 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Discontinued — 2.5MG TABLET ORAL Discontinued — - INDAPAMIDEANI PHARMSANDA 07449819982 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2.5MG TABLET ORAL Discontinued — 1.25MG TABLET ORAL Discontinued — - INDAPAMIDETEVAANDA 07466519972 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Discontinued — 2.5MG TABLET ORAL Discontinued — - INDAPAMIDERISINGANDA 07446119972 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2.5MG TABLET ORAL Rx AB 1.25MG TABLET ORAL Rx AB - INDAPAMIDEWATSON LABSANDA 07458519962 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Discontinued — 2.5MG TABLET ORAL Discontinued — - INDAPAMIDEACTAVIS ELIZABETHANDA 07472219962 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Rx AB 2.5MG TABLET ORAL Rx AB - INDAPAMIDECHARTWELL RXANDA 07459419962 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.25MG TABLET ORAL Discontinued — 2.5MG TABLET ORAL Discontinued — - INDAPAMIDEANI PHARMSANDA 07429919962 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2.5MG TABLET ORAL Rx AB 1.25MG TABLET ORAL Rx AB
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 1983–1998 across 10 FDA applications.
Indapamide: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.